• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aardvark Therapeutics, Inc. - Common Stock (NQ:AARD)

3.880 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.880
Bid (Size) 3.690 (6,000)
Ask (Size) 5.370 (100)
Prev. Close 3.880
Today's Range 3.880 - 3.880
52wk Range 3.350 - 16.60
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is
October 14, 2026
From Grabar Law Office
Via GlobeNewswire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
October 13, 2026
From Pomerantz LLP
Via GlobeNewswire

Performance

52-Week Range 76.6% below 52-week high
3.880
3.3552W Low 16.6052W High
1 Week 23.8% below 1-week high
3.831W Low 5.091W High

Aardvark Therapeutics, Inc. - Common Stock (AARD) traded between $3.35 and $16.60 over the past 52 weeks and last traded at $3.88, 76.6% below its 52-week high. Over the past week it ranged between $3.83 and $5.09.

Past 12 Months
-17.6%
-30.1%
-41.8%
-23.6%
-70.6%
-73.9%
1W -$0.83
1M -$1.67
3M -$2.79
6M -$1.20
YTD -$9.31
1Y -$10.97

AARD was -73.9% over the past year, -23.6% over six months, -70.6% year to date, -17.6% in the last week.

12 Months vs Market
AARD
-73.9%
DIA
+11.4%
SPY
+16.2%
QQQ
+21.9%
IWM
+9.5%

Over the past 12 months AARD returned -73.9% versus DIA (Dow) +11.4%, SPY (S&P 500) +16.2%, QQQ (Nasdaq 100) +21.9% and IWM (Russell 2000) +9.5%.

Volume & Liquidity
1W
180.2K
1M
126.2K
3M
135.7K
6M
201.7K
YTD
227.6K
1Y
222.3K

AARD's 3-month average daily volume is 135.7K.

More News

Read More
News headline image
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. Lawsuit - AARD
October 13, 2026
From SueWallSt
Via GlobeNewswire
News headline image
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
October 13, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 - AARD
October 12, 2026
From Levi & Korsinsky, LLP
Via GlobeNewswire
News headline image
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
October 12, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Duolingo, Inc. (NASDAQ: DUOL); and Ensign Group, Inc. (NASDAQ: ENSG): Grabar Law Office is Investigating Claims on Your Behalf
October 10, 2026
From Grabar Law Office
Via GlobeNewswire
News headline image
URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th
October 10, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
October 09, 2026
From Levi & Korsinsky, LLP
Via ACCESS Newswire
News headline image
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
October 08, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your
October 08, 2026
From Grabar Law Office
Via GlobeNewswire
News headline image
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
October 08, 2026
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
AARD Deadline: Rosen Law Firm Urges Aardvark Therapeutics, Inc. (NASDAQ: AARD) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
October 07, 2026
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
October 06, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); and GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law
October 06, 2026
From Grabar Law Office
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th
October 05, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
If You Lost Money Investing in Aardvark Therapeutics, Inc. (AARD) Contact Robbins LLP for Information About Recovering Your Losses
October 05, 2026
Via Newsfile
Topics Initial Public Offering Lawsuit
News headline image
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
October 05, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Important Notice to Long-Term Shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL); Ardelyx, Inc. (NASDAQ: ARDX); Aardvark Therapeutics, Inc. (NASDAQ: AARD); and GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI): Grabar Law Office is Investigating
October 05, 2026
From Grabar Law Office
Via GlobeNewswire
News headline image
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
AARDVARK DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD
October 02, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
AARD Shareholder Alert: Aardvark Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
October 02, 2026
From Levi & Korsinsky, LLP
Via ACCESS Newswire
News headline image
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
October 01, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th
September 30, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Deadline
September 30, 2026
From Bernstein Liebhard LLP
Via GlobeNewswire

Frequently Asked Questions

Is Aardvark Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aardvark Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aardvark Therapeutics, Inc. - Common Stock trade on?
Aardvark Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aardvark Therapeutics, Inc. - Common Stock?
The ticker symbol for Aardvark Therapeutics, Inc. - Common Stock is AARD on the Nasdaq Stock Market
What is the current price of Aardvark Therapeutics, Inc. - Common Stock?
The current price of Aardvark Therapeutics, Inc. - Common Stock is 3.880
When was Aardvark Therapeutics, Inc. - Common Stock last traded?
The last trade of Aardvark Therapeutics, Inc. - Common Stock was at 10/14/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap